PTC Therapeutics Executive Sells Shares Under Pre-Arranged Plan Amid Strong Analyst Sentiment
Mark Boulding, Executive Vice President and Chief Legal Officer at PTC Therapeutics, Inc. (NASDAQ: PTCT), executed a series of transactions involving the company's common stock on July 6, 2026. The executive sold 5,079 shares valued at $432,117, while simultaneously acquiring an equivalent number of shares through stock option exercises. These move…